SEC 13F Intelligence

Altium Capital Management LLC / PTGX

Altium Capital Management LLC’s Protagonist Therapeutics Inc Position

Does Altium Capital Management LLC own Protagonist Therapeutics Inc (PTGX)? Not currently — the last reported position was 386.0K shares worth $9M in Q1 2022; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$9M
Q1 2022
Shares
386.0K
% of Portfolio
+3.06%
Quarters Held
6
position exited

Position History PTGX

Reported value by quarter
Q4 ’20: $4MQ4 ’20Q1 ’21: $6MQ1 ’21Q2 ’21: $13MQ2 ’21Q3 ’21: $6MQ3 ’21Q4 ’21: $12MQ4 ’21Q1 ’22: $9MQ1 ’22filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2022386.0K$9M+3.06%
Q4 2021346.0K$12M+3.26%
Q3 2021346.0K$6M+1.61%
Q2 2021282.4K$13M+2.94%
Q1 2021238.4K$6M+1.71%
Q4 2020185.9K$4M+1.40%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Altium Capital Management LLC’s full portfolio or all institutional holders of PTGX.